Market Research Logo

Genmab AS (GEN) - Financial and Strategic SWOT Analysis Review

Genmab AS (GEN) - Financial and Strategic SWOT Analysis Review

Genmab AS (GEN) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
HighlightsGenmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Its products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS Key Recent Developments

Mar 29,2019 Constitution of the board of directors in Genmab and grant of restricted stock units and warrants to employees in Genmab
Mar 11,2019 Genmab names Marisol Peron as head of communications and investor relations
Feb 25,2019 Genmab Announces Positive Topline Results in Phase III Study of Subcutaneous Daratumumab in Multiple Myeloma
Feb 20,2019 Genmab 2018 annual report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Genmab A/S - Key Facts
Genmab A/S - Key Employees
Genmab A/S - Key Employee Biographies
Genmab A/S - Major Products and Services
Genmab A/S - History
Genmab A/S - Company Statement
Genmab A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Genmab A/S - Business Description
R&D Overview
Genmab A/S - Corporate Strategy
Genmab A/S - SWOT Analysis
SWOT Analysis - Overview
Genmab A/S - Strengths
Genmab A/S - Weaknesses
Genmab A/S - Opportunities
Genmab A/S - Threats
Genmab A/S - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Genmab A/S, Recent Deals Summary
Section 5 - Company’s Recent Developments
Mar 29, 2019: Constitution of the board of directors in Genmab and grant of restricted stock units and warrants to employees in Genmab
Mar 11, 2019: Genmab names Marisol Peron as head of communications and investor relations
Feb 25, 2019: Genmab Announces Positive Topline Results in Phase III Study of Subcutaneous Daratumumab in Multiple Myeloma
Feb 20, 2019: Genmab 2018 annual report
Nov 26, 2018: Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
Nov 14, 2018: Genmab reports financial results for the first nine months of 2018
Nov 01, 2018: Genmab Announces Data to be Presented at 2018 ASH Annual Meeting
Oct 29, 2018: Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
Oct 21, 2018: Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
Section 6 - Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Genmab A/S, Key Facts
Genmab A/S, Key Employees
Genmab A/S, Key Employee Biographies
Genmab A/S, Major Products and Services
Genmab A/S, History
Genmab A/S, Subsidiaries
Genmab A/S, Key Competitors
Genmab A/S, Ratios based on current share price
Genmab A/S, Annual Ratios
Genmab A/S, Annual Ratios (Cont...1)
Genmab A/S, Interim Ratios
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Genmab A/S, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Genmab A/S, Performance Chart (2014 - 2018)
Genmab A/S, Ratio Charts
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report